Halozyme Therapeutics, Inc. (HALO) is a publicly traded Healthcare sector company. As of May 21, 2026, HALO trades at $69.47 with a market cap of $8.00B and a P/E ratio of 23.31. HALO moved +0.36% today. Year to date, HALO is -3.12%; over the trailing twelve months it is +29.06%. Its 52-week range spans $42.01 to $82.22. Analyst consensus is strong buy with an average price target of $84.48. Rallies surfaces HALO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Which politicians traded HALO stock?
Recent politician trading activity in HALO includes disclosures from Gil Cisneros and Josh Gottheimer. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.
HALO Key Metrics
Key financial metrics for HALO
Metric
Value
Price
$69.47
Market Cap
$8.00B
P/E Ratio
23.31
EPS
$2.96
Dividend Yield
0.00%
52-Week High
$82.22
52-Week Low
$42.01
Volume
266
Avg Volume
0
Revenue (TTM)
$1.51B
Net Income
$348.84M
Gross Margin
82.79%
Congressional Trades in HALO
Gil Cisneros sale HALO on Mar 24, 2025 (amount: $15.00K).
Josh Gottheimer sale HALO on Sep 9, 2024 (amount: $15.00K) for Joint.
Recent politician trading activity in HALO includes disclosures from Gil Cisneros and Josh Gottheimer. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.
Does Rallies track congressional trades in HALO?
Yes. Rallies tracks politician and congressional stock disclosures for HALO, including reported purchases, sales, dates, owners, and trade amounts when available.
Is HALO research on Rallies investment advice?
No. Rallies provides research, data, and educational context for HALO. It does not provide personalized investment advice.
